They're laying the groundwork for legislation and regulation to counter Chinese biopharma companies.
New laws, more regulation of Chinese biopharma under consideration
Julia Demaree Nikhinson/AP
By John WilkersonJune 25, 2026
John Wilkerson, a Washington correspondent, is the author of D.C. Diagnosis, a twice-weekly newsletter about the politics and policy of health and medicine.
John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07.
At BIO, tension over China biotech deal regulation looms
BIO board spoke with national security, health officials on China, CEO says
Bigger, fewer, tougher: the new era of China-US biotech partnerships
HHS, responding to China’s rise, moves to fast-track early drug research
[Bio USA] Korea biotech under pressure from China's rapid rise
China closing in but US leads in biotech quality and commercial reach: survey
PhRMA and BIO mobilize against a wave of anti-China biotech bills in Congress as lawmakers move to curb US dealmaking with China.
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic…
BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall…
A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S.…
Bipartisan Michigan lawmakers unveil a bill subjecting US-China biotech deals to outbound investment screening, citing national…
Two federal lawmakers have introduced a bill seeking to apply the review requi | Two federal lawmakers have introduced a bill…
